These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 24192927)

  • 1. A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma.
    Ross JS; Wang K; Gay LM; Al-Rohil RN; Nazeer T; Sheehan CE; Jennings TA; Otto GA; Donahue A; He J; Palmer G; Ali S; Nahas M; Young G; Labrecque E; Frampton G; Erlich R; Curran JA; Brennan K; Downing SR; Yelensky R; Lipson D; Hawryluk M; Miller VA; Stephens PJ
    Clin Cancer Res; 2014 Jan; 20(1):68-75. PubMed ID: 24192927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2.
    Posada JM; Yakirevich E; Kamat AM; Sood A; Jacob JM; Bratslavsky G; Grivas P; Spiess PE; Li R; Necchi A; Mega AE; Golijanin DJ; Pavlick D; Huang RSP; Lin D; Danziger N; Sokol ES; Sivakumar S; Ross JS; Cheng L
    Mod Pathol; 2024 Mar; 37(3):100424. PubMed ID: 38219954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma.
    Isharwal S; Huang H; Nanjangud G; Audenet F; Chen YB; Gopalan A; Fine SW; Tickoo SK; Lee BH; Iyer G; Chadalavada K; Rosenberg JE; Bajorin DF; Herr HW; Donat SM; Dalbagni G; Bochner BH; Solit DB; Reuter VE; Al-Ahmadie HA
    Hum Pathol; 2018 Jul; 77():63-69. PubMed ID: 29601842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype.
    Zinnall U; Weyerer V; Compérat E; Camparo P; Gaisa NT; Knuechel-Clarke R; Perren A; Lugli A; Toma M; Baretton G; Kristiansen G; Wirtz RM; Cheng L; Wullich B; Stoehr R; Hartmann A; Bertz S
    Hum Pathol; 2018 Oct; 80():55-64. PubMed ID: 29885409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations.
    Ross JS; Wang K; Khaira D; Ali SM; Fisher HA; Mian B; Nazeer T; Elvin JA; Palma N; Yelensky R; Lipson D; Miller VA; Stephens PJ; Subbiah V; Pal SK
    Cancer; 2016 Mar; 122(5):702-11. PubMed ID: 26651075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations.
    Ross JS; Wang K; Sheehan CE; Boguniewicz AB; Otto G; Downing SR; Sun J; He J; Curran JA; Ali S; Yelensky R; Lipson D; Palmer G; Miller VA; Stephens PJ
    Clin Cancer Res; 2013 May; 19(10):2668-76. PubMed ID: 23575477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options.
    Ross JS; Badve S; Wang K; Sheehan CE; Boguniewicz AB; Otto GA; Yelensky R; Lipson D; Ali S; Morosini D; Chliemlecki J; Elvin JA; Miller VA; Stephens PJ
    Arch Pathol Lab Med; 2015 May; 139(5):642-9. PubMed ID: 25927147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human Epidermal Growth Factor Receptor 2 Overexpression in Micropapillary and Other Variants of Urothelial Carcinoma.
    Behzatoğlu K; Yörükoğlu K; Demir H; Bal N
    Eur Urol Focus; 2018 Apr; 4(3):399-404. PubMed ID: 28753766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of tyrosine kinase receptors HER2, EGFR, and VEGFR expression in micropapillary urothelial carcinoma with invasive urothelial carcinoma.
    Li J; Jackson CL; Yang D; Noble L; Wheeler M; MacKenzie D; Adegun T; Amin A
    Target Oncol; 2015 Sep; 10(3):355-63. PubMed ID: 25293577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy.
    Ross JS; Wang K; Al-Rohil RN; Nazeer T; Sheehan CE; Otto GA; He J; Palmer G; Yelensky R; Lipson D; Ali S; Balasubramanian S; Curran JA; Garcia L; Mahoney K; Downing SR; Hawryluk M; Miller VA; Stephens PJ
    Mod Pathol; 2014 Feb; 27(2):271-80. PubMed ID: 23887298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
    Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
    Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome.
    Schneider SA; Sukov WR; Frank I; Boorjian SA; Costello BA; Tarrell RF; Thapa P; Houston Thompson R; Tollefson MK; Jeffrey Karnes R; Cheville JC
    Mod Pathol; 2014 May; 27(5):758-64. PubMed ID: 24186136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic Analysis of Micropapillary Urothelial Carcinoma of the Upper Urinary Tract: Implications for HER2-Targeted Therapy.
    Chou LP; Hsu CW; Yang SF; Lee CT; Ou YC; Lin KC; Hu CY; Jou YC; Tsai YS; Chow NH
    Clin Genitourin Cancer; 2023 Aug; 21(4):508.e1-508.e10. PubMed ID: 37183125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The utility of p63, p40, and GATA-binding protein 3 immunohistochemistry in diagnosing micropapillary urothelial carcinoma.
    Lin X; Zhu B; Villa C; Zhong M; Kundu S; Rohan SM; Yang XJ
    Hum Pathol; 2014 Sep; 45(9):1824-9. PubMed ID: 24993315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive genomic profiling of relapsed and metastatic adenoid cystic carcinomas by next-generation sequencing reveals potential new routes to targeted therapies.
    Ross JS; Wang K; Rand JV; Sheehan CE; Jennings TA; Al-Rohil RN; Otto GA; Curran JC; Palmer G; Downing SR; Yelensky R; Lipson D; Balasubramanian S; Garcia L; Mahoney K; Ali SM; Miller VA; Stephens PJ
    Am J Surg Pathol; 2014 Feb; 38(2):235-8. PubMed ID: 24418857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Micropapillary variant of urothelial carcinoma: a report of 4 cases and literature review.
    Cheng YT; Luo HL; Sung MT; Chiang PH
    Chang Gung Med J; 2010; 33(4):461-5. PubMed ID: 20804677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of micropapillary urothelial carcinoma of the upper urinary tract.
    Sung HH; Cho J; Kwon GY; Jeon HG; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM
    J Clin Pathol; 2014 Jan; 67(1):49-54. PubMed ID: 23940135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms.
    Young G; Wang K; He J; Otto G; Hawryluk M; Zwirco Z; Brennan T; Nahas M; Donahue A; Yelensky R; Lipson D; Sheehan CE; Boguniewicz AB; Stephens PJ; Miller VA; Ross JS
    Cancer Cytopathol; 2013 Dec; 121(12):688-94. PubMed ID: 23893923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.
    Chmielecki J; Ross JS; Wang K; Frampton GM; Palmer GA; Ali SM; Palma N; Morosini D; Miller VA; Yelensky R; Lipson D; Stephens PJ
    Oncologist; 2015 Jan; 20(1):7-12. PubMed ID: 25480824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Invasive micropapillary carcinoma of urinary bladder: a clinicopathological study.
    Chatterjee D; Das A; Radotra BD
    Indian J Pathol Microbiol; 2015; 58(1):2-6. PubMed ID: 25673582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.